Robert Leo Murphy

Grants

Grants per year 1997 2004 2005 2008 2014 2028

• 11 Active
• 115 Finished

Grants per year

Search results

• Finished

  Units for HIV/AIDS Clinical Trials Networks (Northwestern University Clinical Trial Unit)

  Murphy, R. L. (PD/PI), Cohen, B. A. (Co-PD/PI), Flaherty, J. P. (Co-PD/PI), Green, R. (Co-PD/PI), Palella Jr, F. J. (Co-PD/PI), Taiwo, B. O. (Co-PD/PI), Achenbach, C. J. (Co-Investigator), Cohn, S. E. (Co-Investigator), Taiwo, B. O. (Co-Investigator), Flaherty, J. P. (Other), Green, R. (Other), Palella Jr, F. J. (Other), Sutton, S. H. (Other) & Taiwo, B. O. (Other)

  National Institute of Allergy and Infectious Diseases

  2/1/07 → 11/30/13

  Project: Research project

• AIDS Clinical Trials Group Network ("ACTG")

  Murphy, R. L. (PD/PI)

  Social & Scientific Systems, Inc., National Institute of Allergy and Infectious Diseases

  1/1/07 → 5/31/11

  Project: Research project

• Integrated Rapid Test Platforms Appropriate for the Developing World

  Kelso, D. M. (PD/PI), Backman, V. (Co-PD/PI), Colgate, E. (Co-PD/PI), Joseph, R. A. (Co-PD/PI), Lueptow, R. M. (Co-PD/PI), Murphy, R. L. (Co-PD/PI), Peshkin, M. (Other) & Sahakian, A. V. (Other)

  Bill & Melinda Gates Foundation

  8/1/06 → 8/1/10

  Project: Research project

• Integrated Rapid Test Platforms Appropriate for the Developing World: Develop NAT Platform

  Kelso, D. M. (PD/PI), Backman, V. (Co-PD/PI), Colgate, E. (Co-PD/PI), Joseph, R. A. (Co-PD/PI), Lueptow, R. M. (Co-PD/PI) & Murphy, R. L. (Co-PD/PI)

  Bill & Melinda Gates Foundation

  8/1/06 → 8/1/10

  Project: Research project

• Integrated Rapid Test Platforms Appropriate for the Developing World: Develop ICA Platform

  Kelso, D. M. (PD/PI), Backman, V. (Co-PD/PI), Colgate, E. (Co-PD/PI), Joseph, R. A. (Co-PD/PI), Lueptow, R. M. (Co-PD/PI) & Murphy, R. L. (Co-PD/PI)

  Bill & Melinda Gates Foundation

  8/1/06 → 8/1/10

  Project: Research project

• Integrated Rapid Test Platforms Appropriate for the Developing World: Establish Organization

  Kelso, D. M. (PD/PI), Backman, V. (Co-PD/PI), Colgate, E. (Co-PD/PI), Joseph, R. A. (Co-PD/PI), Lueptow, R. M. (Co-PD/PI), Murphy, R. L. (Co-PD/PI) & Sahakian, A. V. (Co-PD/PI)

  Bill & Melinda Gates Foundation

  8/1/06 → 8/1/10

  Project: Research project

• AIDS Clinical Trials Group ACTG

  Murphy, R. L. (PD/PI)

  Social & Scientific Systems, Inc., National Institute of Allergy and Infectious Diseases

  6/1/06 → 5/31/13

  Project: Research project

• Directly Observed, Community-Based Treatment in Nigeria

  Murphy, R. L. (PD/PI) & Taiwo, B. O. (Other)

  Doris Duke Charitable Foundation

  1/1/06 → 6/30/08

  Project: Research project

• Directly Observed, Community-Based Treatment in Nigeria

  Murphy, R. L. (PD/PI) & Taiwo, B. O. (Other)

  Doris Duke Charitable Foundation

  1/1/06 → 6/30/08

  Project: Research project

• A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination with D4T and 3TC in 2NN Patients

  Murphy, R. L. (PD/PI)

  Boehringer Ingelheim Pharmaceuticals, Inc., International Antiviral Therapy Evaluation Center B.V.

  10/10/05 → 5/31/06

  Project: Research project

• A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination with D4T and 3TC in 2NN Patients

  Murphy, R. L. (PD/PI)

  Boehringer Ingelheim Pharmaceuticals, Inc., International Antiviral Therapy Evaluation Center B.V.

  10/10/05 → 5/31/06

  Project: Research project

• Prot# TMC125-C229: An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks

  Murphy, R. L. (PD/PI)

  PPD Development, Tibotec Pharmaceuticals Ltd.

  9/7/05 → 8/12/08

  Project: Research project

• Prot# TMC125-C229: An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks

  Murphy, R. L. (PD/PI)

  PPD Development, Tibotec Pharmaceuticals Ltd.

  9/7/05 → 8/12/08

  Project: Research project

• PROsIT: A Total Patient-Reported Outcomes Solution

  Flaherty, J. P. (PD/PI) & Murphy, R. L. (Co-PD/PI)

  BrightOutcome Inc., National Institute of Mental Health

  7/19/05 → 7/18/08

  Project: Research project

  • Patient-reported Outcomes 100%
  • Clinical Setting 100%
  • Patient-Reported Outcome 100%
  • Reviewed Journal 50%
  • Usability Systems 50%

• PROsIT: A Total Patient-Reported Outcomes Solution

  Flaherty, J. P. (PD/PI) & Murphy, R. L. (Co-PD/PI)

  BrightOutcome Inc., National Institute of Mental Health

  7/19/05 → 7/18/08

  Project: Research project

  • Patient-reported Outcomes 100%
  • Clinical Setting 100%
  • Patient-Reported Outcome 100%
  • Reviewed Journal 50%
  • Assessment Engine 50%

• Nanoemulsions as Adjuvants for Nasal-Spray Vaccines

  Murphy, R. L. (PD/PI)

  University of Michigan, Bill & Melinda Gates Foundation

  7/1/05 → 6/30/09

  Project: Research project

• Nanoemulsions as Adjuvants for Nasal-Spray Vaccines

  Murphy, R. L. (PD/PI)

  University of Michigan, Bill & Melinda Gates Foundation

  7/1/05 → 6/30/09

  Project: Research project

• Prot# A4001026: A Mltcntr, Rndmzd, Dbl-Blind, Comparative Trial Of a Novel CCR5 Antagonist, UK-427,857, in Combination w/Zidovudine/Lamivudine v. Efavirenz in Combination w/Zidovudine/Lamivudine for the Treatment of Antiretroviral-Naïve HIV-1 Infected Sbj

  Murphy, R. L. (PD/PI)

  Quintiles, Inc., Pfizer Inc.

  6/6/05 → 8/8/07

  Project: Research project

• Prot# A4001026: A Mltcntr, Rndmzd, Dbl-Blind, Comparative Trial Of a Novel CCR5 Antagonist, UK-427,857, in Combination w/Zidovudine/Lamivudine v. Efavirenz in Combination w/Zidovudine/Lamivudine for the Treatment of Antiretroviral-Naïve HIV-1 Infected Sbj

  Murphy, R. L. (PD/PI)

  Quintiles, Inc., Pfizer Inc.

  6/6/05 → 8/8/07

  Project: Research project

• Prot# TMC114-C215: An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-Experienced Subjects

  Murphy, R. L. (PD/PI)

  Medisearch International Corp., Tibotec Pharmaceuticals Ltd.

  3/31/05 → 9/2/08

  Project: Research project

• Prot# AI424-075: The SABAR Study: Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study: Endothelial Function in HIV-Infected Subjects Switched to an Atazanavir Regimen

  Murphy, R. L. (PD/PI)

  Bristol-Myers Squibb Company

  2/15/05 → 10/22/10

  Project: Research project

• Prot# MANON 02: A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Immunogenicity and the Safety of Two Schedules of an Homologous Prime-Boost with the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

  Murphy, R. L. (PD/PI)

  ORVACS

  11/29/04 → 12/31/07

  Project: Research project

• Prot# MANON 02: A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Immunogenicity and the Safety of Two Schedules of an Homologous Prime-Boost with the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

  Murphy, R. L. (PD/PI)

  ORVACS

  11/29/04 → 12/31/07

  Project: Research project

• Prot# INCB 8721 RVT-203: A Placebo-Controlled, Double-Blind, Parallel Dose Group Study Exploring the Safety, Tolerability, & Virological Effect of 50, 100, & 200mg Reverset? (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When Used in Co

  Murphy, R. L. (PD/PI)

  Quintiles, Inc., Incyte Corporation

  9/8/04 → 4/13/07

  Project: Research project

• Prot# INCB 8721 RVT-203: A Placebo-Controlled, Double-Blind, Parallel Dose Group Study Exploring the Safety, Tolerability, & Virological Effect of 50, 100, & 200mg Reverset? (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When Used in Co

  Murphy, R. L. (PD/PI)

  Quintiles, Inc., Incyte Corporation

  9/8/04 → 4/13/07

  Project: Research project